Because the AstraZeneca vaccine delay is bad news

12/30/2020 Health, Italy



[ad_1]

EMA “unlikely” to give the green light to AstraZeneca / Oxford vaccine in January. This was stated by the Deputy Executive Director of the European Medicines Agency, Noel Wathion, in an interview with the Belgian newspaper Het Nieuwsblad. “They have not yet been implemented,” he added, stressing that “we need more data on the quality of the vaccine.”

The British pharmacological company does not seem to have doubts about the effectiveness of the vaccine, so much so that just this week Pascal Soriot, CEO of AstraZeneca, told the Sunday Times that it is “95% effective”, such as those already approved by Pfizer and Moderna “,and is capable of 100% elimination of severe symptoms driving to shelters for COVID-19.

If the marketing go-ahead would arrive in England the day after tomorrow and marketing is hypothesized for January 4, the spread in the market of European countries seems destined to be postponed.

An icy shower especially for Italy who bought the AstraZeneca vaccine again in June, together with Germany, France and the Netherlands 400 million doses. They are intended for our country in particular 40.38 million doses, almost double those purchased from the Pfizer / BioNTech consortium (26.92 million), which together with the quantities requested from Moderna, Johnson & Johnson, Sanofi and CureVac, are destined for Italy 202 million doses.

The order entrusted to AstraZeneca (which developed the vaccine in which the Italian company Irbm de Pomezia also participates) was made official by the Minister of Health Roberto Speranza, who in mid-December assumed delivery of at least 10 million doses between January and March.

The delay in the authorization request is due to the fact that tests on the effectiveness will be repeated, following a second experiment with preliminary data that they had not satisfied the scientific community. The circumstance could have an impact on the time of vaccination. of Italian citizens. The European Union would be running for cover, buying 100 million doses of Pfizer / BioNTech.